Targets › PPARD
7 programs from 7 companies in 15 trials: 9 Phase 3, 5 Phase 2, 1 Phase 1; Gastroenterology, Metabolic and endocrine, Oncology; next expected readout Dec 2026.
Ligand-activated transcription factor key mediator of energy metabolism in adipose tissues. Receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. (UniProt, Q03181)
Open in Phaseline: the race on PPARD, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Ipsen | Elafibranor Peroxisome proliferator-activated receptor alpha agonist; Peroxisome proliferator-activated receptor delta agonist | PPARA, PPARD | Phase 3 | Primary Biliary Cholangitis; Primary Biliary Cirrhosis; Primary Biliary Cholangitis (PBC); Primary Sclerosing Cholangitis | Dec 2026 |
| Inventiva Pharma | Lanifibranor (IVA337) Peroxisome proliferator-activated receptor agonist | PPARG, PPARA, PPARD | Phase 3 | NASH - Nonalcoholic Steatohepatitis | Sep 2027 |
| Assistance Publique - Hôpitaux de Paris | Bezafibrate Peroxisome proliferator-activated receptor agonist | PPARG, PPARA, PPARD | Phase 3 | BPC | Dec 2027 |
| Gilead Sciences | Seladelpar Peroxisome proliferator-activated receptor delta agonist | PPARD | Phase 3 | Primary Biliary Cirrhosis; Primary Biliary Cholangitis | Nov 2028 |
| The First Affiliated Hospital of Xiamen University | Chiglitazar Peroxisome proliferator-activated receptor agonist | PPARG, PPARA, PPARD | Phase 2 | Relapsed or Refractory Acute Myeloid Leukemia; Acute Myeloid Leukemia | Dec 2026 |
| Shanghai Jiao Tong University School of Medicine | Chiglitazar Peroxisome proliferator-activated receptor agonist | PPARG, PPARA, PPARD | Phase 2 | MASH - Metabolic Dysfunction-Associated Steatohepatitis | Dec 2030 |
| RDC Clinical | Levagen+ (palmitoylethanolamide, PEA) Lipid signaling molecule; TRPV1 antagonist and PPARδ agonist with anti-inflammatory and ne | TRPV1, PPARD | Phase 2 | Diabetic Peripheral Neuropathy | – |
Primary Biliary Cholangitis (3) Primary Biliary Cirrhosis (2) Primary Sclerosing Cholangitis (2) BPC (2) Primary Biliary Cholangitis (PBC) (1) MASH - Metabolic Dysfunction-Associated Steatohepatitis (1) Relapsed or Refractory Acute Myeloid Leukemia (1) Acute Myeloid Leukemia (1) Diabetic Peripheral Neuropathy (1) NASH - Nonalcoholic Steatohepatitis (1)
small molecule (6)
Ipsen (1) Gilead Sciences (1) Assistance Publique - Hôpitaux de Paris (1) Shanghai Jiao Tong University School of Medicine (1) The First Affiliated Hospital of Xiamen University (1) RDC Clinical (1) Inventiva Pharma (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.